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1 Baker IDI Central Australia,1) · 2 July 2012• The burden of type 2 diabetes mellitus (T2DM) among 
Indigenous children and adolescents is much greater 
than in non-Indigenous young people and appears to be 
rising, although data on epidemiology and 
complications are limited. Young Indigenous people 
living in remote areas appear to be at excess risk of 
T2DM.
• Most young Indigenous people with T2DM are 
asymptomatic at diagnosis and typically have a family 
history of T2DM, are overweight or obese and may have 
signs of hyperinsulinism such as acanthosis nigricans. 
Onset is usually during early adolescence.
• Barriers to addressing T2DM in young Indigenous people 
living in rural and remote settings relate to health service 
access, demographics, socioeconomic factors, cultural 
factors, and limited resources at individual and health 
service levels.
• We recommend screening for T2DM for any Aboriginal 
or Torres Strait Islander person aged > 10 years (or past 
the onset of puberty) who is overweight or obese, has a 
positive family history of diabetes, has signs of insulin 
resistance, has dyslipidaemia, has received 
psychotropic therapy, or has been exposed to diabetes 
in utero.
• Individualised management plans should include 
identification of risk factors, complications, behavioural 
factors and treatment targets, and should take into 
account psychosocial factors which may influence 
health care interaction, treatment success and clinical 
outcomes.
• Preventive strategies, including lifestyle modification, 
need to play a dominant role in tackling T2DM in young 
Indigenous people.
Summaryhe
ve
res
actions th
T  Baker IDI Heart and Diabetes Institute con-ned a group of key clinicians, policymakers andearchers (included as authors) to consider the
at need to be taken to address type 2 diabetes
mellitus (T2DM) in Australian Indigenous (Aboriginal or
Torres Strait Islander) children and adolescents. This article
provides a clinically focused summary of the recommenda-
tions for diagnosing, screening for, managing and prevent-
ing T2DM among Australian Indigenous children and
adolescents living in rural and remote settings. These
recommendations are supported by evidence graded as
follows: high-quality evidence (grade A evidence), inter-
mediate-quality evidence (grade B evidence) or consensus
(grade C evidence). The major recommendations are
shown in Box 1.
Background
Indigenous Australians experience a disproportionately
high rate of T2DM. The most striking features of this
epidemic include the excess risk among those living in
remote settings and the premature age of onset.1 Despite
data being limited, T2DM among Indigenous children and
adolescents appears to be increasing in incidence and the
burden is much greater than that experienced by non-
Indigenous young people.2-4 Indigenous children and ado-
lescents with T2DM typically have a family history of
T2DM and are overweight or obese, and may have signs of
hyperinsulinism such as acanthosis nigricans.2,5 Onset of
T2DM is usually during early adolescence and patients are
often asymptomatic at presentation.2 These findings are
similar to data from the United States.6 Data on comorbid-
ities at diagnosis are lacking and may be a reflection of
poor screening.7 However, the prevalence of microvascular
and macrovascular complications and mortality associated
with T2DM among Indigenous children and adolescents is
r T2DM in children and
erine exposures, including
 modify the expression of
arbohydrate metabolism,9
valent among Indigenous
ctivity, genetic predisposi-
tion and socioeconomic status have been implicated;11 and
the social determinants of health play a central role.12
T2DM during childhood and adolescence can have
significant implications for the young person, their family
and their community.13 It can add considerable strain to
the health system and have a negative influence on the
developmental trajectory of young people.14 Responding
to the growing number of children and adolescents with
T2DM, particularly those living in rural and remote set-
tings, represents a complex challenge for the Australian
health care system.
Diagnosis
Criteria for diagnosis in Indigenous children and adoles-
cents are shown in Box 2. While diagnosis of T2DM can
be made based on random blood glucose levels
(repeated or in combination with symptoms), confirma-
tion of the diagnosis should be made with a fasting
venous blood glucose test, in conjunction with other
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doi: 10.5694/mja12.10036baseline investigations (grade C evidence). Thirst is not
unusual in hot and dry climates, but the combination of
marked polydipsia and polyuria (particularly nocturnal)
is suggestive of diabetes and should lead to screening
(grade C evidence).
The definitions listed in Box 2 relate to laboratory-
measured values. Point-of-care capillary blood glucose
levels have been found to be highly concordant with
laboratory measured blood glucose levels in remote Aus-
tralia; a random point-of-care capillary sample with blood
glucose level  12.2 mmol/L is equivalent to a laboratory-
measured venous sample with blood glucose level  11.1
mmol/L (grade B evidence).16
Oral glucose tolerance tests (OGTTs) can be impractical
in certain circumstances, particularly in rural and remote
settings where health resources are limited. An OGTT
should not be performed if diabetes can be diagnosed
using fasting, random or postprandial criteria as excessive
hyperglycaemia can result.15 OGTTs should not routinely
be used to diagnose T2DM in Indigenous children and
adolescents in rural and remote settings (grade C evi-
dence). If there is doubt about the diagnosis, referral
should be made to a paediatrician or endocrinologist for an
OGTT (grade C evidence).
The use of point-of-care glycated haemoglobin (HbA1c)
testing to diagnose diabetes in adults is recommended,
and is advantageous in remote settings.17 However, no
clear recommendations are yet available for children and
adolescents, and recent data has shown HbA1c testing to
be a poor screener for dysglycaemia and diabetes in
children and adolescents.18 HbA1c testing should therefore
not be used for the diagnosis of T2DM in Indigenous
children and adolescents (grade B evidence).
All children and adolescents with suspected or newly
diagnosed diabetes should have blood or urinary ketone
levels checked. The presence of ketones requires immedi-
ate transfer to hospital and likely management with insulin
until the diagnosis is clarified by further testing (grade C
evidence).
Screening
Recent international guidelines recommend that screening
of asymptomatic young people for T2DM is likely to have a
low yield. However, in populations with a high diabetes
prevalence, clinicians may favour screening while awaiting
more information on effective screening strategies.15,19
At present, the documented burden of T2DM among
Indigenous children and adolescents does not justify pop-
ulation screening. In this context, screening should there-
fore be aimed at enhancing case detection and focused on
Indigenous children and adolescents with features sugges-
tive of an elevated risk of T2DM.
We recommend that any Indigenous Australian over the
age of 10 years (or past the onset of puberty) who is
overweight or obese, has a positive family history of
diabetes, has signs of insulin resistance, has dyslipidaemia,
has received psychotropic therapy, or has been exposed to
2 Criteria for diagnosing T2DM in Indigenous children and 
adolescents15
• Random laboratory-measured* venous BGL  11.1 mmol/L 
and symptoms of both polyuria and polydipsia (particularly 
when these symptoms are nocturnal)
or
• Fasting laboratory-measured venous BGL  7.0mmol/L
(fasting is defined as no intake of calories for at least 8 hours)
or
• Random laboratory-measured* plasma BGL  11.1mmol/L 
on at least two separate occasions
BGL = blood glucose level. T2DM = type 2 diabetes mellitus. * These 
definitions relate to laboratory-measured values. Point-of-care capillary 
BGLs have been found to be highly concordant with laboratory measured 
BGLs in remote Australia; a random point-of-care capillary sample with 
BGL  12.2 mmol/L is equivalent to a laboratory-measured venous sample 
with BGL  11.1 mmol/L (grade B evidence).16 ◆
1 Major recommendations for addressing T2DM in 
Indigenous children and adolescents
Epidemiology and public health
• Improved systems for monitoring the evolution of T2DM in 
Indigenous children and adolescents need to be 
established.
• In parallel, registers of diabetes during pregnancy should be 
established.
Classification and diagnosis
• Standardised methodology, classification and diagnostic 
criteria should be used in all studies of T2DM in Indigenous 
children and adolescents.
• All children and adolescents with newly diagnosed 
diabetes should have blood or urinary ketone levels 
checked to guide initial management of the diabetes. 
Where testing is available, levels of autoantibodies and 
C-peptide should be measured.
Screening and treatment
• Targeted screening of Indigenous Australian children and 
adolescents at risk of diabetes should be performed. Every 
Indigenous child should be screened to determine whether 
they are overweight.
• Opportunities to provide health screening for Indigenous 
children and adolescents should be maximised. Clinics 
should be made as adolescent friendly as possible and 
young people should be offered a comprehensive health 
assessment at each clinical encounter.
• Screening for complications should be undertaken at the 
time of diagnosis and annually thereafter for children and 
adolescents with T2DM.
• Children and adolescents on insulin therapy should have 
access to 24-hour emergency care.
• Health systems should be adequately resourced to respond 
to the demands of screening and follow-up.
• Management plans for treating Indigenous children and 
adolescents with T2DM should be individualised, taking into 
account psychosocial factors. Indigenous health workers 
and patients’ families should be involved, respecting the 
right to confidential health care for older adolescents.
Prevention
• Greater resources and effort should be put into developing 
more effective strategies to prevent childhood obesity and 
T2DM.
• Strategies for the prevention of childhood T2DM need to 
involve program activity at government and societal levels, 
target the social determinants of health, and support 
individual change.
• Programs to prevent obesity need to address barriers to 
physical activity and food security, invest in improving 
maternal and child health (particularly maternal nutrition 
and breastfeeding, and treatment of gestational diabetes), 
and pay greater attention to the conditions in which children 
spend the first years of their lives.
T2DM = type 2 diabetes mellitus. ◆33MJA 197 (1) · 2 July 2012
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Clinical focusdiabetes in utero should be offered screening for T2DM
(grade C evidence). The method of screening for Indige-
nous children and adolescents at risk of T2DM is to test
random blood glucose level in a clinical setting where
adequate interpretation, management and follow-up will
be provided (see Appendix 1; online at mja.com.au). Those
who screen positive almost certainly have T2DM. The
significance of this diagnosis and its impact should not be
underestimated. Patients should be provided with the time
to understand and question the diagnosis, the further
testing and the required treatments. If appropriate, support
from family and Indigenous health workers should be
sought (grade B evidence).20
Management
Challenges in health care delivery in remote areas: Limited
resources at the individual, community and health care
levels pose significant challenges to managing T2DM in
rural and remote settings (Box 3). Food insecurity and
socioeconomic disadvantage can limit opportunities for
lifestyle modification.25,26 Health systems are often over-
stretched, responding to high rates of chronic disease in
adults; they may be less than adequately staffed and may
lack basic resources.27 The combination of these factors
can result in poor and infrequent follow-up for Indigenous
young people with T2DM, limited response to persistent
hyperglycaemia, reluctance to commence and continue
insulin therapy, and limited screening for complications
(grade C evidence).
Engaging Indigenous young people: Engaging young peo-
ple with clinical services to screen for, identify and man-
age T2DM is more likely if the services are accessible,
demonstrate equity in service delivery, are acceptable and
appropriate for the needs and cultural norms of the
community, and are comprehensive and effective.22 Con-
fidentiality is an essential component of providing health
care to young people, particularly in small isolated com-
munities. A young person who does not attend his or her
clinic appointment may still care about their newly diag-
nosed diabetes, and  non-attendance should therefore
trigger further engagement with all necessary social and
family support (grade C evidence).
Initial management: Initial management of T2DM is deter-
mined by symptoms, severity of hyperglycaemia, and the
presence or absence of ketones and ketoacidosis (summa-
rised in Appendix 2; online at mja.com.au).15 Insulin
therapy may be initially required for stabilisation in the
setting of significant hyperglycaemia and ketosis, even in
the absence of ketoacidosis.15 Symptomatic patients, par-
ticularly those with vomiting and dehydration, should be
monitored closely because their condition could deterio-
rate rapidly.
Psychosocial health: Routine psychosocial assessment pro-
motes recognition of and response to psychosocial comor-
bidities, and provides appreciation of the context in which
lifelong management will need to be established and
maintained.30 Psychosocial health is a critical considera-
tion in establishing a care plan (Box 4). Indigenous health
workers play an essential role in the management team,
especially in addressing psychosocial health, and should
be engaged at all stages of management.20
Lifestyle modification: When managing T2DM, the primary
emphasis should be on lifestyle modification.19 It is essen-
tial to engage the family in lifestyle modification, respect-
ing the right to confidential health care for older
adolescents. Engaging the family increases the likelihood
of the young person modifying his or her behaviour, and
may also reduce the risk of diabetes and its complications
within an at-risk family (grade C evidence).
Blood glucose monitoring: The performance and frequency
of self-monitoring of blood glucose levels should be indi-
vidualised, taking into account factors identified during
management planning.15 Once glycaemic control has been
achieved, several fasting values per week and daily post-
prandial measures (taken after the largest meal) are satis-
factory given the values remain in the target range.15 Young
people treated with insulin require more frequent testing
to monitor for hypoglycaemia.
HbA1c levels should be tested quarterly (grade C evi-
dence). International guidelines recommend an HbA1c
target of < 7.5% for all paediatric age groups and < 7% for
adolescents approaching adulthood.15 The Central Aus-
tralian Rural Practitioners Association guidelines recom-
mend, for adults, a target of < 7% for T2DM.34 For
simplicity, an HbA1c target of < 7% is recommended for
Indigenous children and adolescents with T2DM (grade C
evidence).
Oral hypoglycaemic agents and insulin: Currently, met-
formin and insulin are the only hypoglycaemic agents
approved for children and adolescents with T2DM; their
use is shown in Appendix 2.15 Dosing of these medications
should follow local protocols; for children < 14 years of age,
this should be discussed with a paediatrician (grade C
3 Barriers to managing type 2 diabetes mellitus in 
Indigenous children and adolescents living in rural and 
remote settings
Health seeking (grade B evidence)
• Limited contact with health services, relating to:
 perceived “health” despite significant morbidity21
 clinics not being adolescent friendly22
Demographic (grade B evidence)
• Remoteness, limited telecommunication facilities, poor 
school attendance, poor socioeconomic health, no fixed 
address23
Sociocultural (grade C evidence)
• Potential shame of diagnosis24
• Acceptance of poor health status (by individuals and the 
health system)
• Many competing health needs
Physical resources (grade B evidence)
• Limited resources for lifestyle modification25
• Food insecurity26
Clinic resources — physical (grade C evidence)
• Inaccessibility of essential resources (such as glycated 
haemoglobin testing) in many remote clinics27
• Misplaced or broken blood glucose meters
• Lack of infrastructure to start, maintain or safely store insulin
Clinic resources — staffing (grade C evidence)
• Understaffing and high staff turnover28
• Overburdened clinic staff due to acute crisis care29
• Limited and poorly coordinated visiting specialist services ◆1) · 2 July 2012
Clinical focus
tional Diabetes 
t not met
 health workers, social 
h services as required
 health workers, social 
h services as required
 medical officer
 their diabetes; do not 
cial issues; consider 
 escalate treatment; 
vice (Appendix 2)
 their diabetes; do not 
cial issues; consider 
 escalate treatment; 
vice (Appendix 2)
thy diet and exercise, 
mily
thy diet and exercise, 
mily
ACEi
sider statins 
eat hypertension and 
ith ACEi
lmologist
and podiatrist
ol and weight loss for 
 specialist
tructive sleep apnoea 
ted
eption, and PCOS 
munisation, mental 
ds
lood glucose level. 
-density lipoprotein. 
oural modification, 
l performance, literacy, 
eer support; drugs — 
opriate); spirituality — 
◆evidence). Barriers to self-management should be
addressed at each visit.
In commencing insulin therapy, close follow-up is
required to titrate the dose; this may be over the telephone
or in person. All children and adolescents starting on
insulin therapy should have access to emergency care and,
in particular, should be educated about the symptoms,
signs and management of hypoglycaemia (grade C evi-
dence). As diet is often erratic and access to emergency
care for hypoglycaemia may be limited, long-acting basal
insulin may be the best initial choice (grade C evidence).
Screening for complications and comorbidities: Microvascu-
lar complications and risk factors for cardiovascular disease
or actual macrovascular complications may be present at
diagnosis of T2DM among children and adolescents.13 As
a result, screening for complications should be undertaken
at diagnosis and annually thereafter (Box 4). Screening for
complications such as renal disease, hypertension and
retinopathy are of utmost importance in this high-risk
group (grade C evidence).
Specialist referral: Referral to an endocrinologist (or physi-
cian with experience in managing diabetes) and diabetes
educator is recommended at diagnosis and again if glycae-
mic control remains suboptimal despite lifestyle changes
and metformin and insulin therapy (grade C evidence).
Treatment targets: Achieving the goals of treatment (Box 4)
can be a daunting task, and may take some time to
achieve. Any small improvement towards these targets
should be encouraged.
4 Care plan for Indigenous children and adolescents with type 2 diabetes mellitus, adapted from guidelines produced by the Interna
Federation, International Society for Pediatric and Adolescent Diabetes and Asian-Pacific Type 2 Diabetes Group15,19,31,32
Issue to address First visit Quarterly visit Annual visit Target Action if targe
Lifestyle
Psychosocial health ✓ ✓ ✓ Address issues relating to home, 
education and employment, activities, 
drugs, depression, sexuality and 
spirituality*
Engage family, Indigenous
services and mental healt
Behavioural factors ✓ ✓ ✓ Address SNAP: smoking, nutrition, 
alcohol, physical activity33
Engage family, Indigenous
services and mental healt
Diagnostic tests ✓ Complete baseline investigations: 
fasting BGL, autoantibodies (GAD, IA2, 
insulin), C-peptide
Discuss with district
Glycaemic control
BGL ✓ ✓ ✓ Premeal BGL, < 7.2 mmol/L; 
postmeal BGL, < 10.0 mmol/L
Congratulate on addressing
blame; consider psychoso
compliance and need to
consider specialist ad
HbA1c ✓ ✓ ✓ < 7 % (< 53 mmol/mol) Congratulate on addressing
blame; consider psychoso
compliance and need to
consider specialist ad
Weight ✓ ✓ ✓ Reduce body weight Continue to support heal
engage fa
Height, BMI, waist 
circumference 
✓ ✓ BMI < 95th centile (non-obese) Continue to support heal
engage fa
Complications screening
Blood pressure ✓ ✓ ✓ Blood pressure, < 95th centile by age, 
sex and height
Consider 
Fasting lipids (total cholesterol, 
HDL, LDL, triglycerides)
✓ ? ✓ LDL, < 2.6 mmol/L; 
triglycerides, < 1.7 mmol/L
Diet, lifestyle, con
Urea, creatinine, electrolytes, 
ACR, microalbuminuria if 
possible
✓ ? ✓ Refer to local laboratory reference 
intervals
Discuss with specialist; tr
albuminuria w
Eyes: visual acuity, dilated 
fundoscopy
✓ ✓ Monitor and treat retinopathy Refer to ophtha
Feet: pulses and neuropathy ✓ ✓ Monitor and treat neuropathy and 
macrovascular complications
Refer to specialist 
Liver function ✓ ? ✓ Refer to local laboratory reference 
intervals
Maximise glycaemic contr
NAFLD; refer to
Obstructive sleep apnoea ✓ ? ✓ No obstructive symptoms Refer for sleep study if obs
suspec
Opportunistic health screening ✓ ✓ ✓ Consider sexual health (sexually transmitted infections, contrac
screening in patients with oligomenorrhoea, acne or hirsutism), im
health, nutrition (anaemia), and other health nee
✓= perform test. ? = only perform if test result is abnormal on first visit. ACEi = angiotensin-converting enzyme inhibitor. ACR = albumin–creatinine ratio. BGL = b
BMI = body mass index. GAD = glutamic acid decarboxylase. HbA1c = glycated haemoglobin. HDL = high-density lipoprotein. IA2 = insulinoma antigen 2. LDL = low
NAFLD = non-alcoholic fatty liver disease. PCOS = polycystic ovary syndrome.
*A psychosocial assessment should cover: home — who the young person lives with, home environment, family supports for diabetes management and behavi
resources available (refrigeration, telephone, distance to the nearest clinic, availability of emergency care); education and employment — education, educationa
future needs, employment, finances; activities — exercise and patterns of physical activity, eating practices and determinants of these, activities and interests, p
substance use by peers, family and the young person; depression — depressive symptoms, self-harm, suicidal ideation; sexuality — sexual health review (if appr
culture and spirituality.3035MJA 197 (1) · 2 July 2012
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Clinical focusPrevention
Given the relatively poor prognosis for many young people
once a diagnosis of T2DM is made and the continuing
increase in prevalence of T2DM, effective prevention needs
to play a dominant role in tackling this key health problem.
Planned interventions need to be practical and undertaken
with due attention to the demographic, social and cultural
needs of the Indigenous community. They should involve:
• consultation and engagement of communities and
those “at the front line”
• investment in programs that address social determi-
nants of health12
• measurement of the problem and evaluation of action
• appropriate funding and resources.
The immediate benefits of investing in lifestyle modifi-
cation for individuals at risk of T2DM should not be
overlooked. While some clinicians may elect to treat ado-
lescents with obesity and metabolic syndrome (particularly
those with abnormal glucose tolerance) with metformin,
there needs to be an improved evidence base, and out-
come data, before this can be recommended as a strategy.35
In adults, metformin therapy decreases progression of
impaired glucose tolerance to T2DM, but lifestyle modifi-
cation and a small amount of weight loss (average of
5.6 kg) is a more effective intervention.36
Engaging communities and working with Indigenous
health workers is vital for preventing T2DM, not only to
better identify those at risk but also to ensure that preven-
tion efforts are appropriate.
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